Skip Navigation

Journal of Antimicrobial Chemotherapy 2008 62(Supplement 2):ii41-ii54; doi:10.1093/jac/dkn351
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Livermore, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Livermore, D. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

This article appears in the following Journal of Antimicrobial Chemotherapy issue: The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project 1999/2000-2006/7 [View the issue table of contents]

Articles

Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001–06

David M. Livermore1,*, Russell Hope1, Geraldine Brick1, Mark Lillie1, Rosy Reynolds2 on behalf of the BSAC Working Parties on Resistance Surveillance

1 Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK 2 Department of Medical Microbiology, Southmead Hospital, Bristol BS10 5NB, UK


* Correspondence address. Antibiotic Resistance Monitoring and Reference Laboratory, HPA Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK. Tel: +44-20-8327-7223; Fax: +44-20-8327-6264; E-mail: david.livermore{at}hpa.org.uk

Background: Enterobacteriaceae are common agents of bacteraemia, with Escherichia coli accounting for 20% of the cases. Reflecting this importance, members of the family constitute 4 of the 12 collection groups in the British Society for Antimicrobial Chemotherapy (BSAC) Bacteraemia Surveillance Programme.

Methods: MICs from the BSAC surveillance programme were reviewed, along with bacteraemia reports received by the Health Protection Agency (HPA) via its CoSurv/LabBase system. Isolates with unusual resistances were subjected to molecular analysis.

Results: The BSAC and HPA systems both revealed dramatically increasing resistance to cephalosporins, ciprofloxacin and gentamicin among E. coli and Klebsiella spp., with cephalosporin resistance largely contingent on the spread of CTX-M extended-spectrum β-lactamases (ESBLs); fluoroquinolone resistance also increased among Proteus mirabilis and ESBL-negative E. coli. Carbapenem resistance remained extremely rare, but two Enterobacter spp., from the same patient in different years, had KPC carbapenemases, while a few isolates had carbapenem resistance contingent upon combinations of β-lactamase and impermeability, and ertapenem MICs for AmpC-derepressed Enterobacter spp. rose over time. Three new agents—ceftobiprole, doripenem and tigecycline—were tested. Ceftobiprole was broadly active, except against ESBL producers and Klebsiella oxytoca hyperproducing K1 enzyme, and was variable against AmpC-derepressed Enterobacter spp. and against Proteus vulgaris. Doripenem was more potent than imipenem. Tigecycline was almost universally active against E. coli, but low-level non-susceptibility (MIC 2 mg/L) was frequent among Klebsiella spp.

Conclusions: E. coli and Klebsiella spp. showed dramatic shifts, with sharply rising non-susceptibility to cephalosporins, ciprofloxacin and gentamicin. The rise in cephalosporin resistance reflected dissemination of CTX-M ESBLs. Carbapenems remain broadly active and new agents offer potential.

Keywords: BSAC , HPA , surveillance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
D. M. Livermore
Has the era of untreatable infections arrived?
J. Antimicrob. Chemother., September 1, 2009; 64(suppl_1): i29 - i36.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. Reynolds
Antimicrobial resistance in the UK and Ireland
J. Antimicrob. Chemother., September 1, 2009; 64(suppl_1): i19 - i23.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. R. White and on behalf of the BSAC Working Parties on Resistanc
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: a successful collaborative model
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii3 - ii14.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. Reynolds, R. Hope, L. Williams, and on behalf of the BSAC Working Parties on Resistanc
Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii15 - ii28.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. Reynolds, P. C. Lambert, P. R. Burton, and on behalf of the BSAC Extended Working Parties on
Analysis, power and design of antimicrobial resistance surveillance studies, taking account of inter-centre variation and turnover
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii29 - ii39.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.